Cardinal Health, Inc. is an American multinational health care services company.
| Revenue (TTM) | $254.25B |
| Gross Profit (TTM) | $9.77B |
| EBITDA | $4.24B |
| Operating Margin | 1.33% |
| Return on Equity | 0.00% |
| Return on Assets | 3.72% |
| Revenue/Share (TTM) | $1077.32 |
| Book Value | $-12.37 |
| Price-to-Book | 16.07 |
| Price-to-Sales (TTM) | 0.23 |
| EV/Revenue | 0.243 |
| EV/EBITDA | 17.78 |
| Quarterly Earnings Growth (YoY) | 68.80% |
| Quarterly Revenue Growth (YoY) | 5.80% |
| Shares Outstanding | $232.58M |
| Float | $232.04M |
| % Insiders | 0.27% |
| % Institutions | 91.18% |
Volatility is currently contracting
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health is rated Buy, driven by robust growth in its Pharmaceutical and Specialty Solutions segment and precision medicine exposure. PSS revenues reached $234.8 billion in FY2026, up 15% YoY, accounting for 92% of CAH's total revenues, with further growth expected from gene therapy and Solaris Health. Precision medicine, growing at a projected 17% CAGR, positions the company to capture a substantial share of an underserved market, supporting long-term top-line expansion.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Cardinal Health delivered FY2026 non-GAAP EPS of $11.26, exceeding initial guidance and achieving over 30% growth, despite a slight revenue miss. CAH's profit mix is shifting toward higher-margin specialty and 'Other' businesses, making traditional distributor revenue metrics less relevant to earnings power. Management guides 13–15% EPS growth for FY2027, with my estimate at $13.10, implying 7–14% upside to a $258–$275 target range.
Cardinal Health targets 13%-15% fiscal 2027 EPS growth as pharma demand normalizes and specialty, At-Home and buybacks remain key priorities for execution.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CAH and any ticker you trade — then tracks every position and per-strategy win rate.
